A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,901–3,965 of 3,965
Uegami, W., Okoshi, E. N., Lami, K., Nei, Y., Ozasa, M., Kataoka, K., Kitamura, Y., Kohashi, Y., Cooper, L., Sakanashi, H., et al. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101047
York, J. M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6844801
Child, C. E., Ho, L. A., Borders, E., Gray, T., Olson, T., Gordon, B., Cai, H. D., Veras-Tobos, E., Traylor, K., Babu, G., et al. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.07.019
Omran, O., Kalra, A., Muelly, M. C., Reicher, J. J., & Ahmed, R. (2026) · Diagnostics · doi:10.3390/diagnostics16152398
“…interval from initial assessment to final diagnosis in this cohort was 213 days [3], an earlier indication could shorten the diagnostic timeline and accelerate access to antifibrotic therapy, which slows lung-function decline in IPF [30,31] and across progressive fibrosing ILD more broadly [32].”
A self-sustaining repair circuit drives the progression of pulmonary fibrosis
Bach, D., Nguyen, T. K., Pham-The, H., & Nguyen, T. L. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.015 · Cited by 1
Jia, Y., Liu, W., Tang, W., Ou, S., Na, W., Dong, M., & Wei, Y. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261475569
Freund, O., Katsoff, U., Hershko, T., et al. (2026) · Advances in respiratory medicine · doi:10.3390/arm94040057
Li, Z., Song, D., Sun, F., Song, L., An, B., Gao, T., Liu, J., Zhang, K., Liu, K., Wu, K., et al. (2026) · Cell Proliferation · doi:10.1111/cpr.70267
Salvator, H., Simon, N., Mamez, A., Catherinot, É., Roux, A., Suárez, F., Magro, L., & Wallyn, F. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.04.011
STARSHIP: Study of Telomeres And Role of Sex Hormones In Pulmonary fibrosisPreprint
Duckworth, A., Prague, J., Knight, B., Norris, K., Emms, H., Goodrum, S., Crook, C., Sayers, R. R., Steward, M., Thould, H., et al. (2026) · medRxiv · doi:10.64898/2026.08.03.26359301
Srivastava, V. (2026) · Research Square · doi:10.21203/rs.3.rs-10597751/v1
IGF2BP3 promotes early angiogenesis in pulmonary fibrosis by stabilizing HIF-1α
Yang, C., Chen, B., Jing, H., et al. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05684-x
Patil, S. V., GONDHALI, G., & Patil, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10460191/v1
Bonella, F., & Majewski, S. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag133
Li, J., Di, G., Wang, H., Chen, M., Wang, K., Wang, Z., Li, Y., & Wang, T. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.72265
Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights
Lou, K. F., Fulcer, M. M., Lotesto, M. J., Davis, J. M., Serrano, T. P. O., Ma, R., & Ridge, K. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0033-2026
Rukonge, P. A., Kawuribi, V., Lu, Z., Oluwaseun, A. F., Sheng, Y., Yan, K., Zheng, Z., Liu, X., Chu, L., & Yu, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889276
Deng, R., Jiang, S., Han, X., Xiong, M., & Yang, X. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.08.004 · Cited by 1
Sato, Y., Kamio, K., Terasaki, Y., Yoshida, K., Kuse, N., Matsuda, K., Kajimoto, Y., Atsumi, K., Kaburaki, S., Tanaka, T., et al. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00168.2025
Karatavuk, A. O. (2026) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.70240
CUDC-907 attenuates pulmonary fibrosis by reversing HDAC1-mediated SMAD4 deacetylation at lysine 45
Li, Y., Cui, Y., Qiu, H., Fu, K., Shao, C., Chen, Z., Yang, J., Chen, J., Lv, X., Zhou, X., et al. (2026) · Biology Direct · doi:10.1186/s13062-026-00951-9 · Cited by 1
Ren, M., Guihua, S. O. N. G., Xu, Y., Yu, S., Zhang, Y., Sun, M., & Zhang, B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1914253
“Phase III trials showed that both drugs slow forced vital capacity decline or disease progression in IPF, but neither is curative (Richeldi et al., 2014; King et al., 2014).”
Ge, C., & Cui, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177649
“Pirfenidone and nintedanib, together with the recently approved preferential phosphodiesterase 4B inhibitor nerandomilast, demonstrate that the clinical course of IPF is pharmaco-logically modifiable [99–101].”
Turan, O., Uğurlu, E., Tapan, Ö. O., Sarıoğlu, N., Polat, G., Çilekar, Ş., Batum, Ö., & Gülen, Ş. T. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261475558 · Cited by 2
Zhang, Q., Sun, S., Lu, M., Qin, R., Ren, J., Yao, L., Jia, D., Chang, J., Chu, X., Wang, R., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19091374
“…clinical studies have shown that a minority of patients discontinue therapy due to various adverse effects following oral administration, including headache, dyspepsia, nausea, diarrhea, vomiting, fever, hepatic dysfunction, dizziness, skin-related adverse effects, and facial paralysis [14–16].”
InfluentialWang, X., Liu, J., & Sang, A. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154515
Moran-MacDonald, A., Alyami, S., Aldhaheri, S., Kish, M., Davison, S., & Moran‐Mendoza, O. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002726
Kim, M. J., Kwak, H. S., Kim, S., & Kim, H. C. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261484857
The regulatory logic linking inflammation and fibrosis
Alexanian, M., & Srivastava, D. (2026) · Cell · doi:10.1016/j.cell.2026.08.001 · Cited by 3
Bärnthaler, T., Ding, S., Adams, T. S., Rose, K.-A., Rangel, R., Khoury, J., Salimi, M., Anderson, S., Lin, L., Velasco-Alzate, K. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.31.747360
Yang, Y., 刘森玉, Wang, S., Zhang, A., Wang, W., Zhu, Z., Zhang, X., & Liu, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108437
Cough in Interstitial Lung Disease: Current Knowledge and Research Gaps
Giulianelli, G., Bellani, S., Castelli, G., Fiorentù, G., Balestro, E., Birring, S. S., & Spagnolo, P. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00385-8
A multidimensional index with SpO2 at rest for predicting progressive pulmonary fibrosis
Silva, S. A. E. H. C. D., Resende, A. C. L., Mancuzo, E. V., Storrer, K. M., Arantes, L. F. N., Aguiar, F., Soares, M. R., & Pereira, C. A. D. C. (2026) · Respiratory Research & Clinical Practice · doi:10.36416/1806-3756/e20250336
Self-citationGong, K., Zhu, J., Guo, H., Xu, M., Sun, T., Li, Z., Liu, Y., Li, L., Zhang, Y., Liu, C., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05852-2
Li, A., Zhou, G., & Wang, R. (2026) · Toxicology and Industrial Health · doi:10.1177/07482337261486628
Normal age-related decline in forced vital capacity: a systematic review and meta-analysis
Satia, I., Brown, K., Filkowski, J., et al. (2026) · European Respiratory Review · doi:10.1183/16000617.0329-2025
Hepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis
Yilmaz, G., Çoban, H., Erel, F., Akış, M., Sarıoğlu, N., Colak, M., & Şenel, M. Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187023
“Pirfenidone and nintedanib are approved antifibrotic drugs in the treatment of IPF and have been in clinical use since 2014 [5,6].”
Simons, I. A., Wijck, Y. D. W.-V., Brinkman, P., Dekker, T., Korevaar, D. A., Nijman, S. F. M., Boerrigter, B. G., Meijboom, L. J., Sprengers, R. W., Radonic, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10115187/v1
Nagaoka, S., Hara, Y., Fujii, H., et al. (2026) · Canadian Respiratory Journal · doi:10.1155/carj/3604892
Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease
Suzuki, Y., Yoshimura, K., Mori, K., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101510
Divergent Three-Component Assembly of Difluoromethyl 1,3,4-Oxadiazoles
Peng, X., Zeng, X., Liu, J., et al. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c03469
Pitozzi, V., Caruso, P., Pontis, S., Ruscitti, F., Pittelli, M. G., Aquino, G., Volta, R., Pappani, A., Barrea, M., Quaini, F., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188158
“In patients with IPF, pirfenidone, at a maintenance dose of 801 mg three times daily (2403 mg/day), has been shown to slow FVC loss and reduce the risk of disease progression [3].”
Tu, Q., Zhang, X., Zou, Y., Lv, Y., Yan, L., Hou, C., Wang, L., Sun, W., Zhang, H., Pan, M., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1884390
Zhang, X., Wang, Y., & Che, P. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090951
“At the therapeutic level, the two approved antifibrotics for IPF (nintedanib, pirfenidone) [15,16] target broadly expressed growth-factor signaling pathways [36]; consistent with this, nintedanib slows FVC decline across fibrosing ILDs irrespective of the underlying diagnosis [10,14,37].”
Zhou, Y., Huang, Y., Ma, J., Wang, W., Tong, Z., Zhou, Y., Cao, Y., & Dong, Z. (2026) · Non-coding RNA Research · doi:10.1016/j.ncrna.2026.08.003
“Current drugs like pirfenidone and nintedanib only slow disease progression, highlighting the need for new therapeutic targets [3,4].”
Gwon, H. R., Lee, J., Chung, M. P., Jeong, S. H., Song, J. W., Lee, J. H., Lee, H. L., Choi, S. M., Kim, Y. H., Park, S. W., et al. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.08.001 · Cited by 1
Mo'men, M., Saber, S., Amer, A. E., & El‐Kashef, H. A. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118045
Kreuter, M., Kottmann, R. M., Luo, F., Coeck, C., Kanakapura, M., Schlecker, C., Ritter, I., & Handa, T. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03785-z
The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis
Tyker, A., Kuse, N., Pertzov, B., & Kolb, M. R. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2737175
Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy
Zhang, H., Shivnaraine, R. V., Ren, L., Thai, P. N., Janicot, R., Zhu, W., Huang, R., Siepe, D. H., Tu, C., Liu, W., et al. (2026) · Science · doi:10.1126/science.aej5896 · Cited by 2
Johnson, D. C. (2026) · The Open Respiratory Medicine Journal · doi:10.2174/0118743064498371260922043417
Shi, L., Zhan, S., Wang, X., Han, S., Lu, S., Li, R., Xie, J., Yang, C.-Q., Adili, M., Zhang, H., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179372
Oria, R. S., Umeano, V. A., CHUKWU, V. O., Inyang, H. O., & Usin, S. G. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-026-02185-y
Önyılmaz, T., Kizilbay, G. Ö., Kaya, H., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14102176
RAPA triggers SFN-MDM2/p53 to alleviate pulmonary fibrosis via inhibiting AECII senescencePreprint
Liu, M., Du, B., Xu, Z., Cui, X., Li, Z., Huang, L., & Yuan, J. (2026) · Research Square · doi:10.21203/rs.3.rs-10848894/v1
Polystyrene-associated pulmonary fibrosis: a summary based on the available evidence and prospects
Sang, S., Liu, Y., Zhao, H., Wang, B., Lv, G., Feng, S., & Wang, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1953398
Vikas, B., Sweety, V. K., Edison, L. K., & Anil, S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1018053
Camporro, F., & Moyano, V. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2026.102825
Barratt, S. L., Cotton, A., White, P., Wells, M., Hardy, J., Adamali, H. I., & Edey, A. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109168
Arora, P., & Nainwal, L. M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1940560
Li, Z., 耿磊, Li, W., Wang, X., Wang, X., Qin, Z., Zhang, Y., & Mou, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917005
“Antifibrotic agents such as pirfenidone (Noble et al., 2011; King et al., 2014) and nintedanib (Richeldi et al., 2014) have been shown to attenuate the rate of decline in lung function (primarily measured as the forced vital capacity, FVC) among patients with IPF, heralding a new era in disease…”
Therapie der Lungenfibrose – Beginn einer neuen Ära
Behr, J., & Veit, T. (2026) · Pneumologie · doi:10.1055/a-2959-4770
Liang, Y., Xiang, Y., Li, W., Zhang, J., & Shi, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1901489
Zwei neue Hoffnungen auf Progressionshemmung: Idiopathische Lungenfibrose
Markart, P., & Günther, A. (2014) · Pneumo News · doi:10.1007/s15033-014-0025-3
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.